GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK

About this update from Geovax Labs, Inc.

[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Hub to Advance Global Vaccine and Immuno-Oncology Development","length":61,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - March 12, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in the development of immunotherapies and vaccines, today announced its initial steps toward establishing a strategic presence in Europe, with the UK as its initial footprint. This move aligns with the Company's commitment to advancing its vaccine and immunotherapy pipeline through global collaborations.","length":441,"tagName":"p"},{"type":"text","content":"Efforts are underway to identify a UK location best suited to align with GeoVax's development and corporate strategy. The Company already has several established connections in the UK and broader European region, including:","length":227,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Scientific Expertise: Professor Teresa Lambe, a principal investigator at the Oxford Vaccine Group, recently joined GeoVax's Scientific Advisory Board. Professor Lambe played a pivotal role in the development of the Oxford/AstraZeneca COVID-19 vaccine and has extensive experience in vaccine design and evaluation.","length":318,"tagName":"p"}]},{"val":[{"type":"text","content":"Manufacturing Partnerships: GeoVax maintains an existing contract development and manufacturing organization (CDMO) relationship with Oxford Biomedica PLC (Oxford, UK), as well as additional collaborations with Oxford Biomedica (France), with facilities in Strasbourg and Lyon.","length":277,"tagName":"p"}]},{"val":[{"type":"text","content":"Technology Licensing: The Company has a broad licensing agreement with ProBioGen AG (Berlin, Germany) to utilize their AGE1 continuous avian cell line for the manufacture of MVA vaccines.","length":187,"tagNa...

More updates from Geovax Labs, Inc.